ChromaDex Corp.

CDXC on NASDAQToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
9.90US 3.34%1,318,7992.50 - 23.66655.607M

Contact Information

ChromaDex Corp.

Headquarters:
10900 Wilshire Blvd., Suite 600
Los Angeles, California
USA, 90024
Tel: 310-388-6706
Fax: 949-419-0294
Email: Send a message
Website: Visit website
For more information...
Lead: Daniel Gordon

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Rob Fried -Chief Executive Officer

Frank L. Jaksch, Jr. - Co-founder, Executive Chairman of the Board

Kevin Farr - Chief Financial Officer

Mark Friedman - General Counsel and Corporate Secretary

Ben Shichman - Chief Technical Officer

Aron Erickson - Vice President of R&D

Andrew Shao, Ph.D. - Senior Vice President, Global Regulatory & Scientific Affairs

Lisa Hatton Harrington - General Counsel & Corporate Secretary

Frank Fazio - Senior Vice President of Global Business

Rob Fried - Chief Executive Officer

Frank L. Jaksch Jr. - Co-founder, Executive Chairman of the Board

Stephen A. Block - Non-Executive Director

Jeffery Baxter - Non-Executive Director

Kurt Gustafson - Non-Executive Director

Steven D. Rubin - Non-Executive Director

Tony Lau - Non-Executive Director

Wendy Yu - Non-Executive Director

Stock Information

Company Overview

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Management

Rob Fried -Chief Executive Officer

Frank L. Jaksch, Jr. - Co-founder, Executive Chairman of the Board

Kevin Farr - Chief Financial Officer

Mark Friedman - General Counsel and Corporate Secretary

Ben Shichman - Chief Technical Officer

Aron Erickson - Vice President of R&D

Andrew Shao, Ph.D. - Senior Vice President, Global Regulatory & Scientific Affairs

Lisa Hatton Harrington - General Counsel & Corporate Secretary

Frank Fazio - Senior Vice President of Global Business

Board of Directors

Rob Fried - Chief Executive Officer

Frank L. Jaksch Jr. - Co-founder, Executive Chairman of the Board

Stephen A. Block - Non-Executive Director

Jeffery Baxter - Non-Executive Director

Kurt Gustafson - Non-Executive Director

Steven D. Rubin - Non-Executive Director

Tony Lau - Non-Executive Director

Wendy Yu - Non-Executive Director

Contact Information

Headquarters:
10900 Wilshire Blvd., Suite 600
Los Angeles, California
90024, USA
Telephone: 310-388-6706
Fax: 949-419-0294
Email: Send a message
Website: Visit website